A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Study Overview

This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.

Study Description

A phase II study with a safety lead-in of nivolumab in combination with bevacizumab or in combination with bevacizumab and rucaparib for the treatment of relapsed epithelial ovarian, fallopian tube or peritoneal cancer

  • ClinicalTrials.gov Identifier: NCT02873962
  • Protocol Number: 16-263
  • Principal Investigator: Meghan Shea

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000